New pharmacological developments in antidepressants.
The new pharmacological developments in antidepressants are reviewed with particular reference to MAOIs. Combining an MAOI with amitriptyline reduces the risk of a tyramine-induced rise of blood pressure but does not eliminate the risk which is comparable to that of one of the new reversible MAO-A inhibitors (CGP 11305A).
D000639:Amitriptyline / Q000494:pharmacology; D004347:Drug Interactions; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D010880:Piperidines / Q000009:adverse effects; D014439:Tyramine / Q000009:adverse effects
D008996:Monoamine Oxidase Inhibitors; D010880:Piperidines; D000639:Amitriptyline; C038213:brofaromine; D014439:Tyramine